TICKERNERD
Menu
NAGENAGEConsumer Defensive · Packaged Foods

NAGE Stock Forecast: Niagen Bioscience, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$2.99
0.00% on the day

The 6 Wall Street analysts covering Niagen Bioscience, Inc. hold a median 12-month price target of $11 — +251.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 19 Sept 2026 — in the upper half.

Market cap
$236.6M
Ticker Nerd rank
54 / 100
Median analyst target
$11
Analysts covering
6
Revenue$29.8M−4.3% y/y
Operating income$700K
Net income$963K
Free cash flow$2.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
−2.3%
YTD
−53.0%
1Y
−70.5%
From 52W high
−70.8%
From 52W low
+1.0%
$3
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NAGE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Niagen Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Value
97
Issuance
81
Volatility
77
Size
66
Growth
33
Revisions
30
Accruals
18
Momentum
7

Quality (98): The business earns solid, repeatable profits on what it owns.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NAGE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NAGE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Oct 25Jan 26Apr 26Jul 26NAGEHigh $22Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $9Median $11High $22

The green dot is the last close — the median target sits +251.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026HC Wainwright & Co.MaintainsBuy$12 → $11
5 May 2026Canaccord GenuityMaintainsBuy$13 → $10
31 Mar 2026Canaccord GenuityMaintainsBuy—
5 Mar 2026Canaccord GenuityMaintainsBuy—
5 Nov 2025Canaccord GenuityMaintainsBuy—
11 Aug 2025HC Wainwright & Co.MaintainsBuy—
10 June 2025Canaccord GenuityMaintainsBuy—
6 June 2025Roth CapitalMaintainsBuy—
27 May 2025Canaccord GenuityInitiatesBuy—
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
10 Mar 2025HC Wainwright & Co.MaintainsBuy—
5 Mar 2025Ladenburg ThalmannMaintainsBuy—
6 Nov 2024Roth MKMMaintainsBuy—
4 Nov 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NAGE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NAGE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Niagen Bioscience, Inc. returned −70.5% against +16.3% for the S&P 500, dividends included.

NAGE vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26NAGES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NAGE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−62.5%
Analysts raising
0
Analysts cutting
1
Fundamentals

Niagen Bioscience, Inc. (NAGE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.7×

Cheaper than 44% of US stocks

Price / sales
1.8×

Cheaper than 54% of US stocks

Price / book
2.9×

Cheaper than 34% of US stocks

EV / EBITDA
18.0×

Cheaper than 17% of US stocks

Growth & margins
Revenue growth (YoY)
−4.3%

Higher than 21% of US stocks

Earnings growth (YoY)
−73.3%

Higher than 6% of US stocks

Gross margin
64.8%

Higher than 78% of US stocks

Operating margin
2.4%

Higher than 49% of US stocks

Net margin
12.4%

Higher than 74% of US stocks

Returns & dividend
Return on equity
21.8%

Higher than 83% of US stocks

Return on assets
5.4%

Higher than 78% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Niagen Bioscience, Inc. (NAGE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Niagen Bioscience, Inc. has a market value of $236.6M and an enterprise value of $172.8M.

  • Revenue in the twelve months to 30 June 2026: $129.1M. The latest quarter shrank 4.3% year on year.

  • Net income over the same four quarters: $16.0M, a 12.4% net margin.

  • Diluted earnings per share, trailing twelve months: $0.18.

  • Free cash flow in the twelve months to 30 June 2026: $5.7M.

  • Shares outstanding: 78.9M.

  • Trailing P/E: 15.7×; forward P/E: 29.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Niagen Bioscience, Inc. employs 117 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

NAGE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPackaged Foods
CompanyMarket capTKN rank
NAGENiagen Bioscience, Inc.$236.6M
54
BRCCBRC, Inc.$234.3M
75
BGSB&G Foods, Inc.$230.3M
60
NATRNature's Sunshine Products, Inc.$227.8M
84
USNAUSANA Health Sciences, Inc.$258.5M
71
BYNDBeyond Meat, Inc.$197.9M
34
LWAYLifeway Foods, Inc.$362.1M
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Niagen Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NAGE news & analysis

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Business Wire · 17 Sept 2026positive

Niagen Bioscience announced that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the company's small molecule investigational drug candidate targeting rare genetic diseases and aging-related disorders.

Why it matters — NAGE watchers would care because this engagement signals efforts to support the advancement of the company's investigational drug program and strategic business growth.

Niagen Bioscience to Present at Canaccord Genuity's Well Summit

Business Wire · 10 Sept 2026neutral

Niagen Bioscience announced that its CEO Rob Fried and CFO Ozan Pamir will participate in Canaccord Genuity's Well Summit, to be held September 28-30, 2026, in New York. Mr. Fried is scheduled to take part in a session titled "Aging on Trial: Peptides, Hormones, and the Line Between Breakthroughs."

Why it matters — A NAGE watcher would care because the company's executive leadership is gaining visibility at an investor-focused health and wellness summit, potentially raising awareness of the company among the investment community.

Niagen Bioscience to Present at Longevity Investors Conference

Business Wire · 2 Sept 2026neutral

Niagen Bioscience, Inc. announced that senior management will participate in the Longevity Investors Conference held September 14-17, 2026, in Gstaad, Switzerland. CEO Rob Fried will join the "Longevity Goes Mainstream: The Investment Case for Consumer Health" panel on September 16.

Why it matters — The company's presence at a longevity-focused investor conference gives NAGE watchers an opportunity for senior management to present its consumer health investment case directly to relevant investors.

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

Business Wire · 26 Aug 2026positive

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, in San Francisco, CA. Nasdaq is partnering with LD Micro to host 25 curated public companies, each delivering a 15-minute presentation to a room of institutional investors.

Why it matters — NAGE watchers would care because the company is gaining visibility and presenting to institutional investors at a curated Nasdaq-hosted summit, which could raise awareness of its NAD+ and healthy aging focus.

Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club

Business Wire · 20 Aug 2026positive

Niagen Bioscience announced that Tru Niagen, its healthy-aging NAD-boosting supplement, is now available at GNC and Sam's Club retail locations and online at their respective websites. The company said this expansion strengthens its retail footprint.

Why it matters — A NAGE watcher would care because broadening Tru Niagen distribution through major national retailers expands the product's market reach and retail presence.

FAQ

Frequently asked questions about NAGE stock

What is the NAGE stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Niagen Bioscience, Inc. have a median 12-month price target of $11, with estimates ranging from $8.5 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NAGE stock a buy right now?

Of the 6 analysts covering Niagen Bioscience, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Niagen Bioscience, Inc. 54 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NAGE?

As at 19 Sept 2026, Niagen Bioscience, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will NAGE stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +251.2% from the last close, and Ticker Nerd's factor model ranks Niagen Bioscience, Inc. 54 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NAGE stock forecast for 2030?

No analyst covering Niagen Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.5 to $22 over the next 12 months.

How has NAGE stock performed over the past year?

Niagen Bioscience, Inc. returned -70.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Niagen Bioscience, Inc. do?

Niagen Bioscience Inc. is a bioscience company focused on healthy aging and NAD+ science.

What is the latest news on NAGE?

The most recent item we track (Business Wire, 17 Sept 2026): "Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth". Niagen Bioscience announced that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the company's small molecule investigational drug candidate targeting rare genetic diseases and aging-related disorders.

Company

About Niagen Bioscience, Inc.

Niagen Bioscience Inc. is a bioscience company focused on healthy aging and NAD+ science. It develops and commercializes proprietary ingredient technologies and finished dietary supplement products centered on nicotinamide riboside and related NAD+ precursors. The company serves consumer, ingredient, analytical reference standards and services, and pharmaceutical markets through products used in dietary supplements, food and beverage formulations, skin care applications, and research settings. Niagen Bioscience also supplies ingredient raw materials to manufacturers and supports scientific and quality-control work through its analytical and reference standards offerings. Its current portfolio is built around the Niagen platform, which anchors the company’s consumer brands and broader ingredient business, making Niagen Bioscience a specialized participant in the health and wellness, nutraceutical, and bioscience sectors.

CEO Mr. Robert N. Fried · 117 employees · United States · https://www.niagenbioscience.com